OptimizeRx Corporation OPRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 98.65M | 107.35M | 109.43M | 109.51M | 104.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 98.65M | 107.35M | 109.43M | 109.51M | 104.75M |
| Cost of Revenue | 26.42M | 32.16M | 35.83M | 37.99M | 37.30M |
| Gross Profit | 72.24M | 75.18M | 73.60M | 71.52M | 67.45M |
| SG&A Expenses | 49.98M | 49.80M | 50.83M | 53.80M | 52.84M |
| Depreciation & Amortization | 4.29M | 4.30M | 4.33M | 4.34M | 4.36M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.36M | 92.76M | 97.34M | 102.47M | 100.84M |
| Operating Income | 11.30M | 14.59M | 12.09M | 7.03M | 3.91M |
| Income Before Tax | 6.78M | 9.61M | 6.98M | 1.72M | -9.27M |
| Income Tax Expenses | 2.18M | 2.77M | 1.85M | 1.68M | 595.00K |
| Earnings from Continuing Operations | 4.60 | 6.84 | 5.13 | 0.03 | -9.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.60M | 6.84M | 5.13M | 34.00K | -9.87M |
| EBIT | 11.30M | 14.59M | 12.09M | 7.03M | 3.91M |
| EBITDA | 15.75M | 19.05M | 16.58M | 11.52M | 8.40M |
| EPS Basic | 0.25 | 0.37 | 0.27 | 0.00 | -0.54 |
| Normalized Basic EPS | 0.24 | 0.33 | 0.25 | 0.07 | -0.05 |
| EPS Diluted | 0.22 | 0.34 | 0.25 | 0.00 | -0.54 |
| Normalized Diluted EPS | 0.23 | 0.32 | 0.23 | 0.06 | -0.05 |
| Average Basic Shares Outstanding | 74.78M | 74.51M | 74.22M | 73.98M | 73.72M |
| Average Diluted Shares Outstanding | 76.39M | 76.62M | 76.33M | 75.36M | 74.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |